VA Tests Weight-Loss Drug to Help 400K Veterans With Alcohol Use

A medication already changing lives for people with diabetes and obesity might soon help hundreds of thousands of veterans struggling with alcohol addiction.

The Department of Veterans Affairs announced this week it's launching a major clinical trial to test whether semaglutide, the active ingredient in Ozempic and Wegovy, can reduce drinking and improve quality of life for veterans with alcohol use disorder. About 400,000 U.S. veterans currently live with this diagnosis.

The new study will include 600 participants across 18 VA medical centers nationwide. Half will receive semaglutide injections for 24 weeks, while the other half will get a placebo. Researchers will track changes in drinking habits and overall wellness.

This isn't the first hint that GLP-1 drugs might help with addiction. A VA analysis of medical records already showed the medications reduced risk of both alcohol use disorder and abuse of other drugs. A smaller clinical trial with 48 patients found that people taking the drug experienced fewer cravings and drank less on the days they did drink.

Scientists believe the drugs work on addiction similarly to how they help with obesity, by reducing intrusive thoughts about the substance. People taking GLP-1s for weight loss often report that constant "food noise" simply quiets down. Early evidence suggests the same might happen with cravings for alcohol and other drugs.

The Ripple Effect

If the trial succeeds, it could transform addiction treatment for millions of Americans, not just veterans. Alcohol use disorder affects about 29 million people in the United States, and effective treatment options remain limited. Many people don't respond well to current medications or find them hard to stick with long term.

The VA's investment in this research signals a shift toward viewing addiction as a medical condition that might respond to the same kinds of biological interventions that work for diabetes or heart disease. Veterans Affairs Secretary Douglas A. Collins emphasized this approach in the announcement: "We aim to expand the tools available to help Veterans take control of their health and recovery."

The trial builds on growing evidence that GLP-1 drugs have benefits far beyond their original purpose. Researchers are exploring whether they can help with everything from heart disease to certain cancers. Each new possibility offers hope to people who haven't found relief through existing treatments.

Results from this expanded study could arrive within the next few years, potentially opening a new chapter in how we treat addiction.